Article Information
History
- November 18, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ariel Izcovich1,*,
- Reed AC Siemieniuk2,
- Jessica J Bartoszko2,
- Long Ge3,
- Dena Zeraatkar2,
- Elena Kum2,
- Assem M. Khamis4,
- Bram Rochwerg2,
- Thomas Agoritsas2,5,
- Derek K Chu2,6,
- Shelley L McLeod7,8,
- Reem A Mustafa2,9,
- Per O Vandvik10 and
- Romina Brignardello-Petersen2
- 1Servicio de Clinica Médica del Hospital Alemán, Buenos Aires, Argentina
- 2Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main St W, Hamilton, ON L8S 4L8, Canada
- 3Evidence Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, Gansu, China
- 4Hull York Medical School, University of Hull
- 5Division of General Internal Medicine & Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland
- 6Department of Medicine, McMaster University, Hamilton, ON, Canada
- 7Schwartz/Reisman Emergency Medicine Institute, Sinai Health, Toronto, ON, Canada
- 8Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada
- 9Department of Medicine, University of Kansas Medical Center, Kansas City, MO, USA
- 10MAGIC Evidence Ecosystem Foundation, Oslo, Norway
- ↵*Corresponding author; email: ariel.izcovich{at}gmail.com
Posted November 18, 2020.
Adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomized trials
